Intravenous BIBH 1 in Patients With Metastatic Colorectal Cancer

Summary

Study to evaluate the anti-tumour activity, safety and pharmacokinetics of unlabelled sibrotuzumab administered weekly (seven days +/- one day) at a dose of 100 mg (a total of 12 administrations) in patients with metastatic colorectal cancer.

Timeline

Start

2000-02

Primary completion

2000-10

Completion

—

Drugs

Indications